version française rss feed
Fiche concise
Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials.
Bidard F.-C., Fehm T., Ignatiadis M., Smerage J. B., Alix-Panabières C., Janni W., Messina C., Paoletti C., Müller V., Hayes D. F. et al
Cancer and Metastasis Reviews 32, 1-2 (2013) 179-88 - http://www.hal.inserm.fr/inserm-00749450
Versions disponibles :
Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials.
François-Clément Bidard () 1, Tanja Fehm2, Michail Ignatiadis3, Jeffrey Smerage4, Catherine Alix-Panabières5, Wolfgang Janni6, Carlo Messina7, Costanza Paoletti4, Volkmar Müller8, Daniel Hayes4, Martine Piccart3, Jean-Yves Pierga1
1 :  Service d'Oncologie Médicale
Institut Curie
26 rue d'Ulm, 75005 Paris
2 :  Department of Gynecology and Obstetrics
University of Tubingen
Calwer Strasse 7, 72076 Tübingen
3 :  Department of medical oncology
Institut Jules Bordet
4 :  Breast Oncology Program
University of Michigan
Comprehensive Cancer Center, Ann Arbor, Michigan
5 :  Laboratoire cellules circulantes rares humaines
CHRU Montpellier – Hôpital Saint-Eloi
Institut de recherche en biothérapie, 80 avenue Augustin Fliche, F-34295 Montpellier Cedex 5
6 :  Department of Gynecology and Obstetrics
University of Dusseldorf
Moorenstrasse 5, 40225 Düsseldorf
7 :  EORTC - European Organization for Research and Treatment of Cancer
Headquarters, Brussels
8 :  Department of Gynecology
University Medical Center Hamburg-Eppendorf
In 2004, circulating tumor cells (CTC) enumeration by the CellSearch® technique at baseline and during treatment was reported to be associated with prognosis in metastatic breast cancer patients. In 2008, the first evidence of the impact of CTC detection by this technique on survival of cM0(i+) patients were reported. These findings were confirmed by other non-interventional studies, whereas CTC were also investigated as a surrogate for tumor biology, mainly for HER2 expression/amplification. The aim of this report is to present the current prospective large interventional studies that have been specifically designed to demonstrate that CTC enumeration/characterization may improve the management of breast cancer patients: STIC CTC METABREAST (France) and Endocrine Therapy Index (USA) assess the CTC-guided hormone therapy vs chemotherapy decision in M1 patients; SWOG0500 (USA) and CirCe01 (France) assess the CTC count changes during treatment in metastatic patients; DETECT III (M1 patients, Germany) and Treat CTC (cM0(i+) patients, European Organization for Research and Treatment of Cancer/Breast International Group) assess the use of anti-HER2 treatments in HER2-negative breast cancer patients selected on the basis of CTC detection/characterization. These trials have different designs in various patient populations but are expected to be the pivotal trials for CTC implementation in the routine management of breast cancer patients.
Sciences du Vivant/Cancérologie

Articles dans des revues avec comité de lecture
Cancer and Metastasis Reviews (Cancer Metastasis Rev)
Publisher Springer Verlag (Germany)
ISSN 0167-7659 (eISSN : 1573-7233)

cellules tumorales circulantes – circulating tumor cells – breast cancer – cancer du sein – CTC – STIC CTC – CirCe01 – CirCe 01 – ETI score – STIC CTC METABREAST – Detect III – TREAT CTC – CirCe XXX1 – CirCeXXX1 – CirCe T-DM1 – CirCeT-DM1 – phase III trials.
The CirCe01 trial has been funded / supported by La Ligue Contre Le Cancer (#20%), the French ministry of Health (#60%) and Veridex (#20%). The promoter is the Institut Curie.
Liste des fichiers attachés à ce document : 
CTC_trials_hal.doc(400 KB)
CTC_trials_hal.pdf(495.5 KB)